- Builds on CSL Behring's promise and commitment to the transplant community - Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...

Company further increases global manufacturing capabilities with production expansions of albumin in Australia and plasma intermediates in U.S. to meet escalating patient demand for innovative ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The two companies first entered into a partnership to co ...

CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market subcutaneous (SC) injection 200mg Andembry pens designed to prevent acute ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

KING OF PRUSSIA, Pa., June 12, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) ...

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into ...

Garadacimab is a novel, first-in-class, recombinant monoclonal antibody for hereditary angioedema that targets activated Factor XII. The FDA has accepted a Biologics License Application (BLA) for CSL ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. At BIO 2019, happening June 3 to 6 at the Convention Center ...

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...